Similarly, an integrated analysis incorporating clinical characteristics, genetic profiling and venetoclax response data from primary AML patient samples determined that high BCL2A1 expression was one of the most significant factors which predicted resistance to venetoclax [53]. The gene discussed is BCL2A1; the disease is acute myeloid leukemia.